The AZN share price has stumbled. Is now a good time to buy the stock?

The AstraZeneca share price has fallen to a valuation that makes the stock look cheap compared to its growth potential, says this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

positive mental health woman

Image source: Getty Image

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price outperformed the FTSE 100 by a substantial margin in 2020. However, over the past 12 months, the stock has lagged the UK’s leading equity index.

Excluding dividends, shares in AstraZeneca have returned -1%. Meanwhile, the lead index has added nearly 18%. Over the past month, shares in the pharmaceutical giant have lost 4%, compared to a flat FTSE 100. 

This performance seems to suggest the market has become disinterested in the enterprise. But I think that could be a mistake. Indeed, the company’s latest trading update indicates to me the group is stronger than ever. 

AZN share price growth 

AstraZeneca has risen to fame over the last year as the company’s cheap and effective coronavirus vaccine has saved tens of thousands of lives. The decision to sell the vaccine at cost to many customers has generated a spate of good publicity for the group. In the second quarter, the company generated $900m of sales from its coronavirus vaccine. In the same period, US drug giant Pfizer reported sales of $7.8bn for its treatment.

The company’s vaccine catapulted it onto the front pages of newspapers worldwide, but it’s only a tiny part of the overall business. In the second quarter, group sales totalled $8.2bn. Rising sales of treatments to emerging markets and oncology helped boost revenues 31% year-on-year. 

Based on these revenue trends, City analysts expect the company to report earnings per share of around 523p this year. This suggests the AZN share price is trading at a forward price-to-earnings (P/E) multiple of 22. Further growth of 28% is expected in 2022. Based on these targets, the stock’s selling at a 2022 P/E of 17.3. 

These numbers don’t look to me to be particularly demanding. The stock’s trading at roughly the same valuation as its FTSE 100 peer, Hikma. What’s more, a 2022 P/E of 17.3 implies the AZN share price is dealing at a PEG ratio of less than one. This implies the stock may offer growth at a reasonable price. 

Of course, these are just forecasts. There’s no guarantee the company will hit earnings projections in the years ahead. 

Risks and challenges

If the company’s growth doesn’t live up to expectations, the stock may be expensive at current levels. Challenges the group may face include higher research and development costs. Regulatory delays in approving new treatments may also hold back growth.

AstraZeneca’s sales have also faced pressure in the past as its treatments have lost patent protection, allowing competitors to manufacture the same drug at a lower cost. 

Despite these potential headwinds, I think the recent performance of the AZN share price could offer an opportunity. That’s why I’d buy the stock for my portfolio today.

The national champion has a market-leading position in vaccines and oncology, and its current valuation suggests the market is overlooking its long-term growth potential. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »